Published in Breast Cancer Res on August 20, 2010
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst (2003) 9.68
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell (2004) 8.06
Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol (2006) 5.92
Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer (2002) 4.57
Cluster analysis of gene expression dynamics. Proc Natl Acad Sci U S A (2002) 3.83
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics (2008) 3.24
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Res (2010) 1.65
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res (2006) 4.95
Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov (2012) 4.72
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Intraclonal competition limits the fate determination of regulatory T cells in the thymus. Nat Immunol (2009) 3.38
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol (2013) 3.24
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst (2008) 3.21
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol (2005) 2.77
Antigen-specific peripheral shaping of the natural regulatory T cell population. J Exp Med (2008) 2.68
Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol (2011) 2.38
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park) (2009) 2.28
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
The Cancer Genome Atlas: clinical applications for breast cancer. Oncology (Williston Park) (2013) 2.19
US breast cancer mortality trends in young women according to race. Cancer (2014) 2.07
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics (2012) 2.01
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res (2009) 2.01
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79
Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. J Matern Fetal Neonatal Med (2010) 1.77
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol (2009) 1.64
Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther (2004) 1.63
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res (2012) 1.56
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res (2011) 1.56
Renal transplant imaging using magnetic resonance angiography with a nonnephrotoxic contrast agent. Transplantation (2013) 1.54
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res (2012) 1.52
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat (2006) 1.51
Peripheral lung function in patients with stable and unstable asthma. J Allergy Clin Immunol (2013) 1.50
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest (2012) 1.49
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res (2012) 1.47
Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol (2010) 1.47
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg (2009) 1.46
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat (2009) 1.46
18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med (2011) 1.45
Outcomes in kidney transplant recipients from older living donors. Transplantation (2015) 1.42
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A (2009) 1.42
Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat (2009) 1.28
Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clin Proc (2010) 1.24
Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res (2012) 1.23
Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer (2011) 1.19
Papillary squamous cell carcinoma of the head and neck: clinicopathologic and molecular features with special reference to human papillomavirus. Am J Surg Pathol (2013) 1.18
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J Clin Oncol (2010) 1.17
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res (2009) 1.16
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat (2013) 1.10
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat (2012) 1.10
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat (2011) 1.10
CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. Cancer Res (2011) 1.09
Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat (2012) 1.05
Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer (2009) 1.03
Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. Mol Cancer Ther (2013) 1.02
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol (2010) 1.01
Neoadjuvant endocrine therapy for locally advanced breast cancer. Semin Oncol (2006) 1.01
A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer. Breast Cancer Res Treat (2010) 1.00
Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest (2014) 1.00
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat (2013) 0.99
Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway. Breast Cancer Res (2005) 0.98
A quantitative histomorphometric classifier (QuHbIC) identifies aggressive versus indolent p16-positive oropharyngeal squamous cell carcinoma. Am J Surg Pathol (2014) 0.95
Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res (2011) 0.95
Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. Mol Endocrinol (2014) 0.94
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res (2011) 0.94
A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. Cancer (2012) 0.94
Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res Treat (2013) 0.93
Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth. Mol Cancer Res (2011) 0.92
Dramatic response of choroidal metastases from breast cancer to a combination of trastuzumab and vinorelbine. Breast J (2004) 0.90
Successful targeting of ErbB2 receptors-is PTEN the key? Cancer Cell (2004) 0.89
Molecular pathways: extracting medical knowledge from high-throughput genomic data. Clin Cancer Res (2013) 0.88
Molecular profiling of triple negative breast cancer. Breast Dis (2010) 0.88
F11R is a novel monocyte prognostic biomarker for malignant glioma. PLoS One (2013) 0.87
Neoadjuvant endocrine therapy for breast cancer: more questions than answers. J Clin Oncol (2005) 0.87
Gastrointestinal lymphomas in a North American population: clinicopathologic features from one major Central-Midwestern United States tertiary care medical center. Diagn Pathol (2012) 0.87
Tumor cell anaplasia and multinucleation are predictors of disease recurrence in oropharyngeal squamous cell carcinoma, including among just the human papillomavirus-related cancers. Am J Surg Pathol (2012) 0.86
Cyclin D1-a prognostic marker in oropharyngeal squamous cell carcinoma that is tightly associated with high-risk human papillomavirus status. Hum Pathol (2013) 0.86
Postoperative imaging surveillance in pediatric pilocytic astrocytomas. J Neurosurg Pediatr (2010) 0.86
Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data. PLoS One (2013) 0.86
Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. Gynecol Oncol (2010) 0.85
Incorporating genomics into breast cancer clinical trials and care. Clin Cancer Res (2013) 0.85
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. Nat Rev Clin Oncol (2012) 0.85
Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. Steroids (2011) 0.84
Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males. J Clin Invest (2014) 0.84
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol (2008) 0.84
A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. Mod Pathol (2013) 0.83
T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement. Am J Surg Pathol (2014) 0.82